5 completed, 1 active not recruiting, 1 enrolling by invitation, 1 recruiting. 9 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Active not recruiting 1, Enrolling by invitation 1, Recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Enrolling by invitation 1, Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Hereditary Angioedema (HAE): new trials by email Literature Review of Hereditary Angioedema (HAE) trials Research Report on Hereditary Angioedema (HAE)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule - Hereditary Angioedema (HAE), Angioedema | Phase 1 / Phase 2 | Recruiting | Institute for Asthma and Allergy | 10 | 2025-03-10 | 2025-07-02 |
| A Phase 2 in Adult Subjects With Hereditary Angioedema BW-20805 - Hereditary Angioedema (HAE) | Phase 2 | Active not recruiting | Shanghai Argo Biopharmaceutical Co., Ltd. | 25 | 2025-02-28 | 2026-04-17 |
| Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 / Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 150 | 2022-12-28 | 2026-07-21 |
| Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema BCX7353, Placebo - Hereditary Angioedema (HAE) | Phase 2 | Completed | BioCryst Pharmaceuticals | 58 | 2017-07-31 | 2021-04-01 |
| Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema BCX7353, Placebo - Hereditary Angioedema (HAE) | Phase 2 | Completed | BioCryst Pharmaceuticals | 75 | 2016-08-01 | 2021-03-23 |
| Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks CINRYZE with rHuPH20 - Hereditary Angioedema (HAE) | Phase 2 | Completed | Shire | 47 | 2013-02-04 | 2021-06-03 |
| Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema ecallantide - Hereditary Angioedema (HAE) | Phase 2 / Phase 3 | Withdrawn | Shire | 2012-06-01 | 2021-05-18 | |
| CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 CINRYZE - Hereditary Angioedema (HAE) | Phase 2 | Completed | Shire | 9 | 2010-06-02 | 2021-06-03 |
| EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema DX-88 (ecallantide) - Hereditary Angioedema (HAE) | Phase 2 | Completed | Shire | 77 | 2003-11-01 | 2021-05-18 |
Angioedemas, Hereditary (9) · Angioedema (1) · Hereditary Angioedema Type III (1) · Hereditary Angioedema Types I and II (1)
Cardiovascular Diseases (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (9) · Hereditary Complement Deficiency Diseases (9) · Hypersensitivity (9) · Hypersensitivity, Immediate (9) · Immune System Diseases (9) · Immunologic Deficiency Syndromes (9) · Primary Immunodeficiency Diseases (9) · Skin Diseases (9) · Skin Diseases, Vascular (9) · Skin and Connective Tissue Diseases (9) · Urticaria (9) · Vascular Diseases (9) · Angioedema (8)
Complement C1 Inhibitor Protein (2) · SERPING1 protein, human (2) · berotralstat (2) · ecallantide (2)
Shire (4) · BioCryst Pharmaceuticals (2) · Institute for Asthma and Allergy (1) · Pharvaris Netherlands B.V. (1) · Shanghai Argo Biopharmaceutical Co., Ltd. (1)
Germany (6) · United States (5) · Hungary (4) · Italy (4) · Spain (4) · Austria (3) · Poland (3) · United Kingdom (3) · Australia (2) · Canada (2) · Denmark (2) · France (2) · Israel (2) · North Macedonia (2) · Sweden (2)
Hilary Longhurst, MBBS, PhD (1) · Markus Magerl, Doctor (1)
PMID 36326435, PMID 36408587, PMID 23878046, PMID 24712435, PMID 26171584, PMID 27931305, PMID 30044938
2023 (1)